Stock Comparison
DXCM vs JNJ
Dexcom Inc vs Johnson & Johnson
The Verdict
DXCM takes this one.
Head-to-Head
Market Cap
P/E Ratio
Profit Margin
Return on Equity
Debt-to-Equity
Overall Risk
DVR Score
The Deep Dive
Dexcom maintains its strong position as a market leader in the Continuous Glucose Monitoring (CGM) sector, driven by the ongoing global rollout of G7 and promising initial traction for Stelo in the Type 2 non-insulin market. The company showcases a clear strategic vision for significant Total Addressable Market (TAM) expansion, supported by robust R&D and regulatory expertise, solid financial heal...
Full DXCM AnalysisJohnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...
Full JNJ AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Analyze Any Stock →Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.